子宫内膜癌淋巴结清扫与临床结局:5546例患者的人群基础研究
基于慕尼黑癌症登记处1998至2016年诊断的子宫内膜癌患者数据,分析风险适配淋巴结清扫策略的实施情况。5446例可评估患者中,低危、中/高危和中危组分别占58.5%、30.1%和11.4%,淋巴结清扫率分别为20.2%、53.0%和63.7%,淋巴结受累率分别为1.7%、9.6%和19.3%。各风险组内清扫与未清扫患者的局部复发、淋巴结复发或远处转移时间无显著差异,调整年龄和合并症后总生存也无显著差异。
要点
- 低危、中/高危、高危组淋巴结清扫率分别为20.2%、53.0%、63.7%。
- 低危、中/高危、高危组淋巴结受累率分别为1.7%、9.6%、19.3%。
- 各风险组内清扫与未清扫患者的复发和生存均无显著差异。
核心结论
- 真实世界中早期子宫内膜癌风险适配淋巴结清扫管理存在较高的手术不足和过度治疗率。
- 相应生存数据未显示系统淋巴结清扫有显著获益。
- 作者认为未来需前瞻性试验、新手术概念和预后标志物来改善早期子宫内膜癌的管理和结局。
研究设计与样本
- 基于人群的慕尼黑癌症登记处数据分析,纳入1998年至2016年诊断的子宫内膜癌患者。
- 共5446例可评估患者,按风险分组分析淋巴结清扫实施情况与临床结局。
主要发现
- 低危、中/高危和高危组分别占58.5%、30.1%和11.4%。
- 低危、中/高危和高危组淋巴结清扫率分别为20.2%、53.0%和63.7%。
- 低危、中/高危和高危组淋巴结受累率分别为1.7%、9.6%和19.3%。
- 各风险组内清扫与未清扫患者的局部复发、淋巴结复发或远处转移时间无显著差异。
- 调整年龄和合并症状态后,总生存无显著差异。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: According to current treatment guidelines, comprehensive surgical staging procedures in endometrial cancer confined to the uterus depend on uterine risk factors: a systematic lymph node dissection (LND) is recommended in high risk patients and should be omitted in low risk patients. Its role in intermediate and high intermediate risk patients is inconclusive. The aim of this analysis was to review the implementation of this risk-adopted strategy. MATERIALS AND METHODS: Data were provided by the population-based Munich Cancer Registry. Patients with endometrial cancer diagnosed between 1998 and 2016 were included. RESULTS: Of 5446 eligible patients, 58.5%, 30.1% and 11.4% belonged to the low risk, intermediate/high-intermediate and high risk group, respectively. Lymph node dissection was performed in 20.2%, 53.0% and 63.7% within these groups. Lymph node involvement was diagnosed in 1.7%, 9.6% and 19.3%, respectively. Within these risk groups, there was no significant difference in the time to local recurrence, lymph node recurrence or distant metastases between patients with and without LND. After adjusting for age and comorbidity-status, no significant difference in overall survival was found. CONCLUSIONS: The application of a risk-adopted management of LND in early endometrial cancer in real-life is associated with a high rate of surgical under- and overtreatment. Corresponding survival data do not show a significant benefit of a systematic lymph node dissection. In order to improve the management and outcome of early endometrial cancer in the future, prospective trials, new surgical concepts and prognostic markers will be primary and necessary.
引用
- Pölcher M, Rottmann M, Brugger S, et al. Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients. Gynecol Oncol. 2019. PMID: 31027900. doi:10.1016/j.ygyno.2019.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。